Our Technology
Our Pipeline
Our pipeline includes EXiVO approach derived in vivo CAR-T therapeutics for autoimmune diseases, infectious diseases, neurological disorders, hemato-oncology indications. Our initial focus is to develop therapies for autoimmune disease by reprogramming extracorporeally derived T cells that develop in vivo and deplete pathogenic B cells
TQx Pipeline
- Program
- Pre-Clinic
- IND-Enabling
- Phase 1/2
- Phase 3
TQ-1001 (TQx Own)
Indication: Autoimmune
Transfection Method: LNPs
Integration: Transient
Target: CD19
Selection Marker: CD-3 (T-Cells)
TQ-1002
Indication: Infectious Disease
Integration: Stable
Transfection Method: Viral
Target: undisclosed
Selection Marker: CD-3
TQ-1003
Indication: Hemato-Onco
Integration: Stable
Transfection Method: CRISPR-CAS
Viral Target: undisclosed
Selection Marker: CD-3
TQ-1004
Indication: Neurology (NMDR or Gliobl.)
Integration: Transient
Transfection Method: LNPs
Target: CAAR
Selection Marker: CD-3
TQ-1005
Indication: Longevity
Integration: Transient
Transfection
Method: LNPs
Target: CD57
Selection Marker: CD-3
You might be interested in
Get in touch!
If you are interested in our technology or platform, feel free to reach out!
TQ Therapeutics GmbH
Fraunhoferstr. 1
82152 Planegg Germany
Phone: +49 89 / 248 870 4 - 50
Email: info@tqtherapeutics.com